BACKGROUND AND PURPOSE: Statin pretreatment has been associated with improved outcomes in patients with ischemic stroke. Although several mechanisms have been examined in animal models, few have been examined in patients. We hypothesized that patients using statins before stroke onset may have greater reperfusion than patients not using statins. METHODS: Acute ischemic stroke patients underwent 2 MR scans: within 4.5 (tp1) and at 6 hours (tp2) after stroke onset. Regions of reperfusion were defined by prolonged mean transit time (MTT) at tp1, which normalized at tp2. Four MTT thresholds were assessed to ensure that results were not spuriously based on an arbitrary threshold. Baseline characteristics, relative reperfusion, and change in NIHSS between tp1 and 1-month follow-up (ΔNIHSS) were compared between patients who were using statins at stroke onset and those who were not. RESULTS: Thirty-one stroke patients were prospectively enrolled; 12 were using statins and 19 were not. Baseline characteristics did not differ between the 2 groups except the statin group had greater coronary artery disease (P=0.03). Patients using statins showed significantly greater reperfusion compared to untreated patients across all MTT thresholds. For MTT of 4 seconds, median relative reperfusion was 50% (interquartile range, 30%-56%) in the preexisting statin group versus 13% (interquartile range, 5%-36%) in the untreated group (P=0.014). The statin group had greater ΔNIHSS (8.8±4.0 points) compared to the untreated group (4.4±5.7 points; P=0.028). CONCLUSIONS: Statin use before ischemic stroke onset was associated with greater early reperfusion and NIHSS improvement. Further studies in larger populations are required to confirm our preliminary findings.
BACKGROUND AND PURPOSE: Statin pretreatment has been associated with improved outcomes in patients with ischemic stroke. Although several mechanisms have been examined in animal models, few have been examined in patients. We hypothesized that patients using statins before stroke onset may have greater reperfusion than patients not using statins. METHODS:Acute ischemic strokepatients underwent 2 MR scans: within 4.5 (tp1) and at 6 hours (tp2) after stroke onset. Regions of reperfusion were defined by prolonged mean transit time (MTT) at tp1, which normalized at tp2. Four MTT thresholds were assessed to ensure that results were not spuriously based on an arbitrary threshold. Baseline characteristics, relative reperfusion, and change in NIHSS between tp1 and 1-month follow-up (ΔNIHSS) were compared between patients who were using statins at stroke onset and those who were not. RESULTS: Thirty-one strokepatients were prospectively enrolled; 12 were using statins and 19 were not. Baseline characteristics did not differ between the 2 groups except the statin group had greater coronary artery disease (P=0.03). Patients using statins showed significantly greater reperfusion compared to untreated patients across all MTT thresholds. For MTT of 4 seconds, median relative reperfusion was 50% (interquartile range, 30%-56%) in the preexisting statin group versus 13% (interquartile range, 5%-36%) in the untreated group (P=0.014). The statin group had greater ΔNIHSS (8.8±4.0 points) compared to the untreated group (4.4±5.7 points; P=0.028). CONCLUSIONS: Statin use before ischemic stroke onset was associated with greater early reperfusion and NIHSS improvement. Further studies in larger populations are required to confirm our preliminary findings.
Authors: Minoru Asahi; Zhihong Huang; Sunu Thomas; Shin-ichi Yoshimura; Toshihisa Sumii; Tatsuro Mori; Jianhua Qiu; Sepideh Amin-Hanjani; Paul L Huang; James K Liao; Eng H Lo; Michael A Moskowitz Journal: J Cereb Blood Flow Metab Date: 2005-06 Impact factor: 6.200
Authors: Leslie N Johnson-Anuna; Gunter P Eckert; Cornelia Franke; Urule Igbavboa; Walter E Müller; W Gibson Wood Journal: J Neurochem Date: 2007-01-04 Impact factor: 5.372
Authors: Tavarekere N Nagaraja; Robert A Knight; Richard L Croxen; Kirthi P Konda; Joseph D Fenstermacher Journal: Neurol Res Date: 2006-12 Impact factor: 2.448
Authors: Sung Sug Yoon; James Dambrosia; Julio Chalela; Mustapha Ezzeddine; Steven Warach; Joseph Haymore; Lisa Davis; Alison E Baird Journal: BMC Med Date: 2004-03-23 Impact factor: 8.775
Authors: Mi Ji Lee; Oh Young Bang; Suk Jae Kim; Gyeong Moon Kim; Chin Sang Chung; Kwang Ho Lee; Bruce Ovbiagele; David S Liebeskind; Jeffrey L Saver Journal: Cerebrovasc Dis Date: 2014-01-16 Impact factor: 2.762
Authors: Madhuvanthi A Kandadai; Jason Meunier; Christopher J Lindsell; George J Shaw; Mitchell S V Elkind Journal: Curr Neurovasc Res Date: 2012-08 Impact factor: 1.990
Authors: Laura C Gioia; Mahesh Kate; Rebecca McCourt; Bronwen Gould; Shelagh B Coutts; Dariush Dowlatshahi; Negar Asdaghi; Thomas Jeerakathil; Michael D Hill; Andrew M Demchuk; Brian Buck; Derek Emery; Ashfaq Shuaib; Kenneth Butcher Journal: J Cereb Blood Flow Metab Date: 2015-03-11 Impact factor: 6.200